ID

38064

Beschrijving

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01597193

Link

https://clinicaltrials.gov/show/NCT01597193

Trefwoorden

Versies (1)
  1. 14-09-19 14-09-19 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

14 september 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Breast Cancer NCT01597193

Engels

Eligibility Breast Cancer NCT01597193

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically confirmed breast cancer with accompanying pathology report;
Beschrijving

Breast Carcinoma

Datatype

boolean

Alias
UMLS CUI [1]
C0678222
submit unstained representative tumor specimen, either as a paraffin block (preferred) or ≥ 10 unstained slides
Beschrijving

Tumor tissue sample Unstained Paraffin Block | Tumor tissue sample Unstained Slide Quantity

Datatype

boolean

Alias
UMLS CUI [1,1]
C0475358
UMLS CUI [1,2]
C1883469
UMLS CUI [1,3]
C1519524
UMLS CUI [2,1]
C0475358
UMLS CUI [2,2]
C1883469
UMLS CUI [2,3]
C1265611
received at least 2 lines of systemic therapy in the advanced setting (for enzalutamide alone arm only);
Beschrijving

Systemic therapy Quantity Advanced disease | Enzalutamide Protocol Arm

Datatype

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0679246
UMLS CUI [2,1]
C3496793
UMLS CUI [2,2]
C1522541
eastern cooperative oncology group performance (ecog) status of 0 or 1;
Beschrijving

ECOG performance status

Datatype

boolean

Alias
UMLS CUI [1]
C1520224
estimated life expectancy of at least 3 months
Beschrijving

Life Expectancy Estimated

Datatype

boolean

Alias
UMLS CUI [1,1]
C0023671
UMLS CUI [1,2]
C0750572
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
severe concurrent disease, infection, or comorbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment;
Beschrijving

Comorbidity Severe | Communicable Disease Severe | Study Subject Participation Status Inappropriate

Datatype

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205082
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C0205082
UMLS CUI [3,1]
C2348568
UMLS CUI [3,2]
C1548788
pregnant or lactating;
Beschrijving

Pregnancy | Breast Feeding

Datatype

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
known or suspected brain metastasis or leptomeningeal disease;
Beschrijving

Metastatic malignant neoplasm to brain | Metastatic malignant neoplasm to brain Suspected | Leptomeningeal Neoplasm | Leptomeningeal Neoplasm Suspected

Datatype

boolean

Alias
UMLS CUI [1]
C0220650
UMLS CUI [2,1]
C0220650
UMLS CUI [2,2]
C0750491
UMLS CUI [3]
C0751297
UMLS CUI [4,1]
C0751297
UMLS CUI [4,2]
C0750491
history of another malignancy within the previous 5 years other than curatively treated in situ carcinomas;
Beschrijving

Cancer Other | Exception Curative treatment Carcinoma in Situ

Datatype

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1273390
UMLS CUI [2,3]
C0007099
for patients who are enrolled to receive enzalutamide plus anastrozole or exemestane or fulvestrant must not have received tamoxifen or any medication known to be a potent cyp3a4 inducer or inhibitor.
Beschrijving

Enrollment | Enzalutamide Plus Anastrozole | exemestane | fulvestrant | Tamoxifen Absent | CYP3A4 Inducers Strong Absent | CYP3A4 Inhibitors Strong Absent

Datatype

boolean

Alias
UMLS CUI [1]
C1516879
UMLS CUI [2,1]
C3496793
UMLS CUI [2,2]
C0332287
UMLS CUI [2,3]
C0290883
UMLS CUI [3]
C0851344
UMLS CUI [4]
C0935916
UMLS CUI [5,1]
C0039286
UMLS CUI [5,2]
C0332197
UMLS CUI [6,1]
C3850041
UMLS CUI [6,2]
C0442821
UMLS CUI [6,3]
C0332197
UMLS CUI [7,1]
C3850053
UMLS CUI [7,2]
C0442821
UMLS CUI [7,3]
C0332197
Terug naar het begin van de pagina

Similar models

Eligibility Breast Cancer NCT01597193

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Breast Carcinoma
Item
histologically confirmed breast cancer with accompanying pathology report;
boolean
C0678222 (UMLS CUI [1])
Tumor tissue sample Unstained Paraffin Block | Tumor tissue sample Unstained Slide Quantity
Item
submit unstained representative tumor specimen, either as a paraffin block (preferred) or ≥ 10 unstained slides
boolean
C0475358 (UMLS CUI [1,1])
C1883469 (UMLS CUI [1,2])
C1519524 (UMLS CUI [1,3])
C0475358 (UMLS CUI [2,1])
C1883469 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Systemic therapy Quantity Advanced disease | Enzalutamide Protocol Arm
Item
received at least 2 lines of systemic therapy in the advanced setting (for enzalutamide alone arm only);
boolean
C1515119 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0679246 (UMLS CUI [1,3])
C3496793 (UMLS CUI [2,1])
C1522541 (UMLS CUI [2,2])
ECOG performance status
Item
eastern cooperative oncology group performance (ecog) status of 0 or 1;
boolean
C1520224 (UMLS CUI [1])
Life Expectancy Estimated
Item
estimated life expectancy of at least 3 months
boolean
C0023671 (UMLS CUI [1,1])
C0750572 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Comorbidity Severe | Communicable Disease Severe | Study Subject Participation Status Inappropriate
Item
severe concurrent disease, infection, or comorbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment;
boolean
C0009488 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C2348568 (UMLS CUI [3,1])
C1548788 (UMLS CUI [3,2])
Pregnancy | Breast Feeding
Item
pregnant or lactating;
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Metastatic malignant neoplasm to brain | Metastatic malignant neoplasm to brain Suspected | Leptomeningeal Neoplasm | Leptomeningeal Neoplasm Suspected
Item
known or suspected brain metastasis or leptomeningeal disease;
boolean
C0220650 (UMLS CUI [1])
C0220650 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0751297 (UMLS CUI [3])
C0751297 (UMLS CUI [4,1])
C0750491 (UMLS CUI [4,2])
Cancer Other | Exception Curative treatment Carcinoma in Situ
Item
history of another malignancy within the previous 5 years other than curatively treated in situ carcinomas;
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1273390 (UMLS CUI [2,2])
C0007099 (UMLS CUI [2,3])
Enrollment | Enzalutamide Plus Anastrozole | exemestane | fulvestrant | Tamoxifen Absent | CYP3A4 Inducers Strong Absent | CYP3A4 Inhibitors Strong Absent
Item
for patients who are enrolled to receive enzalutamide plus anastrozole or exemestane or fulvestrant must not have received tamoxifen or any medication known to be a potent cyp3a4 inducer or inhibitor.
boolean
C1516879 (UMLS CUI [1])
C3496793 (UMLS CUI [2,1])
C0332287 (UMLS CUI [2,2])
C0290883 (UMLS CUI [2,3])
C0851344 (UMLS CUI [3])
C0935916 (UMLS CUI [4])
C0039286 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C3850041 (UMLS CUI [6,1])
C0442821 (UMLS CUI [6,2])
C0332197 (UMLS CUI [6,3])
C3850053 (UMLS CUI [7,1])
C0442821 (UMLS CUI [7,2])
C0332197 (UMLS CUI [7,3])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial